JP2024508171A - 肉腫の処置のための置換３，６－ジヒドロ－２ｈ－１，３，４－オキサジアジン－２－オン - Google Patents

肉腫の処置のための置換３，６－ジヒドロ－２ｈ－１，３，４－オキサジアジン－２－オン Download PDF

Info

Publication number
JP2024508171A
JP2024508171A JP2023553692A JP2023553692A JP2024508171A JP 2024508171 A JP2024508171 A JP 2024508171A JP 2023553692 A JP2023553692 A JP 2023553692A JP 2023553692 A JP2023553692 A JP 2023553692A JP 2024508171 A JP2024508171 A JP 2024508171A
Authority
JP
Japan
Prior art keywords
dihydro
oxadiazin
trifluoromethyl
phenyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023553692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508171A5 (enExample
Inventor
マルティン・ランゲ
シュテファン・カウルフース
シャルロッテ・クリスティーネ・コーピッツ
ハイディ・グロイリッヒ
シャオユン・ウ
マシュー・メイヤーソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of JP2024508171A publication Critical patent/JP2024508171A/ja
Publication of JP2024508171A5 publication Critical patent/JP2024508171A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023553692A 2021-03-03 2022-03-02 肉腫の処置のための置換３，６－ジヒドロ－２ｈ－１，３，４－オキサジアジン－２－オン Pending JP2024508171A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156193P 2021-03-03 2021-03-03
US63/156,193 2021-03-03
PCT/EP2022/055211 WO2022184748A1 (en) 2021-03-03 2022-03-02 Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma

Publications (2)

Publication Number Publication Date
JP2024508171A true JP2024508171A (ja) 2024-02-22
JP2024508171A5 JP2024508171A5 (enExample) 2025-03-11

Family

ID=80780814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023553692A Pending JP2024508171A (ja) 2021-03-03 2022-03-02 肉腫の処置のための置換３，６－ジヒドロ－２ｈ－１，３，４－オキサジアジン－２－オン

Country Status (7)

Country Link
US (1) US20230405015A1 (enExample)
EP (1) EP4301371A1 (enExample)
JP (1) JP2024508171A (enExample)
CN (1) CN117279644A (enExample)
CA (1) CA3212314A1 (enExample)
TW (1) TW202302113A (enExample)
WO (1) WO2022184748A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120187704A (zh) * 2022-11-24 2025-06-20 盛睿泽华医药科技（苏州）有限公司 吡啶酮化合物及其制备方法和用途
CN118420559B (zh) * 2023-04-27 2025-02-14 上海超阳药业有限公司 氘代噁二嗪酮化合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500369A (ja) * 2013-10-17 2017-01-05 サルタル セラピューティクス エルティーディＳａｒｔａｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ ヒト患者の固形腫瘍の治療に用いるためのホスホジエステラーゼ阻害剤含有組成物
JP2018531892A (ja) * 2015-08-13 2018-11-01 ザ・ブロード・インスティテュート・インコーポレイテッド Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法
JP2019508404A (ja) * 2016-02-05 2019-03-28 バイエル・ファルマ・アクティエンゲゼルシャフト 癌患者の層別化および癌治療のための化合物、組成物および方法
JP2020506934A (ja) * 2017-02-03 2020-03-05 ザ・ブロード・インスティテュート・インコーポレイテッド 癌治療のための化合物、組成物および方法
JP2020529439A (ja) * 2017-08-04 2020-10-08 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジヒドロオキサジアジノン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150361A (en) * 1998-12-22 2000-11-21 Bayer Corporation Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
CN106573931A (zh) * 2014-06-18 2017-04-19 拜耳医药股份有限公司 抑制BET蛋白的具有间位取代的芳族氨基或醚基的3，4‑二氢吡啶并[2，3‑b]吡嗪酮

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500369A (ja) * 2013-10-17 2017-01-05 サルタル セラピューティクス エルティーディＳａｒｔａｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ ヒト患者の固形腫瘍の治療に用いるためのホスホジエステラーゼ阻害剤含有組成物
JP2018531892A (ja) * 2015-08-13 2018-11-01 ザ・ブロード・インスティテュート・インコーポレイテッド Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法
JP2019508404A (ja) * 2016-02-05 2019-03-28 バイエル・ファルマ・アクティエンゲゼルシャフト 癌患者の層別化および癌治療のための化合物、組成物および方法
JP2020506934A (ja) * 2017-02-03 2020-03-05 ザ・ブロード・インスティテュート・インコーポレイテッド 癌治療のための化合物、組成物および方法
JP2020529439A (ja) * 2017-08-04 2020-10-08 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジヒドロオキサジアジノン

Also Published As

Publication number Publication date
EP4301371A1 (en) 2024-01-10
TW202302113A (zh) 2023-01-16
WO2022184748A1 (en) 2022-09-09
CN117279644A (zh) 2023-12-22
US20230405015A1 (en) 2023-12-21
CA3212314A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
US12486248B2 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH
US11787797B2 (en) 4,5-annulated 1,2,4-triazolones
US20230064809A1 (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US20230357239A1 (en) Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
WO2024079252A1 (en) Sos1 inhibitors
US12258323B2 (en) Dihydrooxadiazinones
US10179123B2 (en) 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors
US11660301B2 (en) Combination of ATR kinase inhibitors with PARP inhibitors
AU2022258751A1 (en) Phosphorus derivatives as novel sos1 inhibitors
US20230405015A1 (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
WO2018122168A1 (en) Combinations of bub1 kinase and parp inhibitors
WO2018153971A1 (en) Combination of atr kinase inhibitors
US20210369724A1 (en) Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
EP4661870A1 (en) Combinations of dgk (diacylglycerol kinase) inhibitors
JP2017522332A (ja) アミノ置換イソオキサゾール類
WO2018215282A1 (en) Combination of bub1 and pi3k inhibitors
HK40105245A (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
WO2018158175A1 (en) Combination of bub1 inhibitors
WO2021260443A1 (en) Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260707